Transformation of human urothelial cells (UROtsa) by As3+ and Cd2+ induces the expression of keratin 6a

Environmental Health Perspectives

Volumn 116, Issue 4, 2008, Pages 434-440

  Somji, Seema ^a   Bathula, Chandra S ^a   Zhou, Xu Dong ^a   Sens, Mary Ann ^a   Sens, Donald A ^a   Garrett, Scott H ^a  

^a UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Arsenic; Bladder cancer; Cadmium; Keratin; Urothelium; UROtsa

Indexed keywords

ARSENIC TRIOXIDE; BIOLOGICAL MARKER; CADMIUM; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; INSULIN; KERATIN; KERATIN 6A; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; CELL CULTURE; CELL TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR XENOGRAFT; UROTHELIUM; WESTERN BLOTTING;

ANIMALS; ARSENITES; BLOTTING, WESTERN; CADMIUM; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CULTURE MEDIA; EPIDERMAL GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN; KERATIN-6; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSPLANTATION, HETEROLOGOUS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 45749156390     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.10279     Document Type: Article

References (41)

1. Achtstatter T, Moll R, Becht E, Balcarova-Stander J, Franke WWW. 1988. Cytokeratins in normal and malignant transitional epithelium. Am J Pathol 132:123-144.
2. Akdas A, Turkeri L. 1991. The impact of squamous metaplasia in transitional cell carcinoma of the bladder. Int Urol Nephrol 23:333-336.
3. Bossuyt V, Fadare O, Martel M, Ocal IT, Burtness B, Moinfar F, et al. 2005. Remarkably high frequency at EGFH expression in breast carcinomas with squamous differentiation. Int J Surg Pathol 13:319-327.
4. Chiou HY, Hsueh YM, Liaw KF, Horng SF, Chiang MH, Pu YS, et al. 1995. Incidence of internal cancer and ingested inorganic arsenic: a 7-year follow-up study in Taiwan. Cancer Res 55:1296-1300.
5. Chu PG, Weisst LM. 2001. Cytokeratin 14 expression in epithelial neoplamsn: a survey of 435 cases with emphasis on its value in differentiating squamous call carcinomas from other epithelial neoplasms. Histopathology 39:9-16.
6. Chu PG, Weiss LM. 2002. Keratin expression in human tissue and neoplasms. Histopathology 40:403-439.
7. Chu PG, Wu E, Weiss LM. 2000. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 13:962-972.
8. Frazier HA, Robertson JE, Dodge RK, Paulson DF. 1993. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 71:3993-4001.
9. Garcia-Rio I, Penes PF, Garcia-Diaz A, Mclean WN, Smith FJ. 2005. A severe case of pachyonychia congenita type I due to a novel proline mutation in keratin 6a. Br J Dermatol 152:800-802.
10. Kitchin KT. 2001. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 172:249-261.
11. Lindgren A, Vahter M, Dencker L. 1982. Autoradiographic studies on the distribution of arsenic in mice and hamsters administered 74As-arsenite or -arsenate. Acta Pharmacol Toxicol (Copenh) 51:253-265.
12. Logothetis CJ, Dexeus FH, Chong C, Sella A, Ayala AG, Ro JY, et al. 1989. Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the MD Anderson experience. J Urol 141:33-37.
13. Luster MI, Simeonova PP. 2004. Arsenic and urinary bladder cell proliferation. Toxicol Appl Pharmacol 198:419-423.
14. Maloney ME. 1996. Arsenic in dermatology. Dermatol Surg 22: 301-304.
15. Malzahn K, Mitze M, Thoenes M, Moll R, 1998. Biological and prognostic significance of stratified epithelial cytokeratins in filtrating ductal breast carcinomas. Virchows Arch 433: 119-129.
16. Martin JE, Jenkins BJ, Zuk RJ, Blandy JP, Baithun SI. 1989. Clinical importance of squamous metaplasia in invasive transitional cell carcinoma of the bladder. J Clin Pathol 42: 250-253.
17. Moll R. 1998. Cytokeratins as markers of differentiation in the diagnosis of epithelial tumors. In: Intermediate Filaments. Subcelluar Biochemistry. Vol 31 (Herrmann H, Harris JR, ads). Now York:Plenum Press, 205-281.
18. Moll R, Krepler R, Franke WW. 1983. Complex cytokeratin polypeptide patterns observed in certain human carcinomas. Differentiation 23:256-269.
19. NIH. 2002. PHS Policy on Humane Care and Use of Laboratory Animals. Bethesda, MD:National Insittutes of Health. Available: http://grants.nih.gov/grants/olaw/references/PHSPolicyLabAnimals.pdf [accessed 25 January 2008].
20. Paladini RD, Takahashi K, Bravo NS, Coulombe PA. 1996. Onset of re-epithelialization after skin injury correlates with a reorganization of keratin filaments in wound edge keratinocytes: defining a potential role for keratin 16. J Cell Biol 132:381-397.
21. Pelzoldt JL, Leigh IM, Duffy PG, Masters JR. 1994. Culture and characterization of human urotbelium in vivo and in vitro. Urol Res 22:67-74.
22. Petzoldt JL, Leigh IM, Duffy PG, Sexton C. Masters JR. 1995. Immortalisation of human urothelial cells. Urol Res 23: 377-380.
23. Rossi MR, Masters JR, Park S, Todd JH, Garrett SH, Sens MA, et al. 2001. The immortalized UROtsa cell line as a potential cell culture model of human urothelium. Environ Health Perspect 109:801-808.
24. Safer JD, Crawford TM, Hollick MF. 2004. A role for thyroid hormone in wound healing through keratin gene expression. Endocrinology 145:2357-2361.
25. Schaafsma HE, Ramaekers FC, van Muijen GN, Lane EB, Leigh IM, Robben H, et al. 1990. Distribution of cytokeratin polypetides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression. Am J Pathol 136:329-343.
26. Schweizer J, Bowden PE, Coulombe PA, Langbein L, Lane EB, Magin TM, et al. 2006. New consensus nomenclature for mammalian keratins. J Cell Biol 174:169-174.
27. Sens DA, Park S, Gurel V, Sens MA, Garrett SH, Somji S. 2004. Inorganic cadmium- and arsenite-induced malignant transformation of human bladder urothelial cells. Toxicol Sci 79:56-63.
28. Sesterhenn AM, Mandic R, Dunne AA, Werner JA. 2005. Cytokeratins 6 and 16 are frequently expressed in head and neck squamous cell carcinoma cell lines and fresh biopsies. Anticancer Res 25:2675-2680.
29. Smedts F, Ramaekers F, Troyanovsky S, Pruszczynski M, Link M, Lane B, et al. 1992. Keratin expression on cervical cancer. Am J Pathol 141:497-511.
30. Smiley AK, Klingenberg JM, Boyce ST, Supp OM. 2006. Keratin expression in cultured skin substitutes suggests that the hyperproliferative phenotype observed in vitro is normalized after grafting. Burns 32:135-138.
31. Smith AH, Goycolea M, Haque R, Biggs ML. 1998. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 147:660-669.
32. Stoler A, Duvic M, Fuchs E. 1989. Unusual pattern of keratin expression in the overlying epidermis of patients with dermatofibromas: biochemical alterations in the epidermis as a consequence of dermal tumors. J Invest Dermatol 93: 728-738.
33. Stoler A, Kopan R, Duvic M, Fuchs E. 1988. Use of monospecific antisera and cRNA probes to localize the major changes in keratin expression during normal and abnormal epidermal differentiation. J Cell Biol 197:427-446.
34. Sun TT. 2006. Altered phenotype of cultured urothelial and other stratified epithelial cells: implications for wound healing. Am J Physiol Renal Physiol 291:F9-F21.
35. Takahashi K, Coulombe PA. 1997. Defining a region of the human keratin 6a gene that confers inducible expression in stratified epithelia of transgenic mice. J Biol Chem 272: 11979-11985.
36. Takahashi K, Paladini RD, Coulombe PA. 1995. Cloning and characterization of multiple human genes and cDNAs encoding highly related type II keratin 6 isoforms. J Biol Chem 270:18581-18592.
37. Tort T. Patterns of distribution of cytokeratins 20 and 7 in special types of invasive breast carcinoma: a study of 123 cases. 1999. Ann Diagn Pathol 3:350-356.
38. Tsuda T, Babazono A, Yamamoto E, Kurumatani N, Mino Y, Ogawa T, et al. 1995. Ingested arsenic and internal cancer: a historical cohort study followed for 33 years. Am J Epidemiol 141:198-209.
39. Wang YN, Chang WC. 2003. Induction of disease-associated keratin 16 gene expression by epidermal growth factor is regulated through cooperation of transcription factors Sp1 and c-Jun. J Biol Chem 278:45848-45857.
40. Ward KM, Cook-Bolden FE, Christiana AM, Colebi JT. 2003. Identification of a recurrent mutation in keratin 6a in a patient with overlapping clinical features of pachyonychia congenita types 1 and 2. Clin Exp Dermatol 26:434-436.
41. Wojcik SM, Bundman DS, Roop DR. 2000. Delayed wound healing in keratin 6a knockout mice. Mol Cell Biol 20:5248-5255.